Use of mometasone furoate for treating airway passage and lung disease

Abstract

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

1 . A method of treating a corticosteroid-responsive disease of the upper, or lower airway passages or of the lungs in patients afflicted with said disease, which comprises administering once-a-day to the surfaces of said passages or lungs of said patients a substantially non-systematically bioavailable amount of aerosolized particles of mometasone furoate effective for treating said disease. 
     
     
         2 . The method of  claim 1  wherein the disease is allergic or nonallergic rhinitis of the upper airway passages. 
     
     
         3 . The method of  claim 1  wherein the disease is an allergic or inflammatory disease of the lower airway passages and/or lungs. 
     
     
         4 . The method of  claim 1  wherein the disease is asthma. 
     
     
         5 . A method of treating allergic or non-allergic rhinitis in patients afflicted with said rhinitis which comprises administering once-a-day to the surfaces of the upper airway passages of said patients an amount of aerosolized particles of mometasone furoate effective to maximize topically treating said rhinitis in the upper airway passages while simultaneously substantially minimizing systemic bioavailability thereof. 
     
     
         6 . The method of  claim 5  wherein the mometasone furoate is administered intranasally. 
     
     
         7 . The method of  claim 5  wherein the amount of mometasone furoate administered is in the range of about 25 to about 800 micrograms/day. 
     
     
         8 . The method of  claim 5  wherein the mometasone furoate is administered in the form of an aqueous suspension. 
     
     
         9 . A method of treating allergic and/or inflammatory diseases of the lower airway passages and/or lung in patients afflicted with at least one of said diseases which comprises administering once-a-day via oral administration to the surfaces of the upper and lower airway passages of said patients an amount of mometasone furoate effective to maximize topically treating said allergic and/or inflammatory diseases in the lower airway passage and/or lungs while simultaneously substantially minimizing the systemic bioavailability thereof. 
     
     
         10 . The method of  claim 9  wherein the disease treated is an inflammatory disease. 
     
     
         11 . The method of  claim 9  wherein the inflammatory disease treated is a inflammatory disease associated with chronic obstruction pulmonary disease. 
     
     
         12 . The method of  claim 9  wherein the disease treated is a granulomtous disease of the lungs, and upper and lower airway passages. 
     
     
         13 . The method of  claim 9  wherein the disease treated is a non-malignant proliferative and/or inflammatory disease of the lungs. 
     
     
         14 . The method of  claim 13  wherein the non-malignant proliferative and/or inflammatory disease of idiopathic pulmonary fibrosis. 
     
     
         15 . The method of  claim 9  wherein the diseased treated is bronchopulmonary dysphasia. 
     
     
         16 . The method of  claim 9  wherein the disease treated is hypersensitivity pneumonitis. 
     
     
         17 . The method of  claim 9  wherein the (inflammatory) amount of mometasone furoate administered is in the range of about 10 to about 5000 micrograms/days. 
     
     
         18 . A method of treating asthma in a patient afflicted with asthma which comprises administering once-a-day to the surfaces of the lower airway passages and lungs of the patient an amount of aerosolized particles of mometasone furoate effective to maximize treating asthma in the lower airway passages and lungs while simultaneously substantially minimizing systemic bioavailability thereof. 
     
     
         19 . The method of  claim 18  wherein the amount of mometasone furoate administered is in the range of about 50 to about 1000 micrograms/day. 
     
     
         20 . The method of  claim 18  wherein the mometasone furoate is administered by oral inhalation. 
     
     
         21 . The method of  claim 20  wherein a metered dose inhaler is used to administer the mometasone furoate in the amount of about 50 to about 1000 micrograms a day. 
     
     
         22 . The method of  claim 20  wherein a dry powder inhaler is used to administer the mometasone furoate in the amount of 100 to 600 micrograms a day. 
     
     
         23 . The method of  claim 19  wherein the mometasone furoate is intranasally administered. 
     
     
         24 . The method of  claim 23  wherein the mometasone furoate is administered intranasally in the form of an aqueous suspension. 
     
     
         25 . A method of producing a rapid onset of action in treating asthma in patients afflicted with asthma which comprises administering via oral inhalation to the lower airway passages and lungs of said patients a non-systematically bioavailable amount of aerosolized particles of mometsone furoate effective for producing said accelerated onset of action. 
     
     
         26 . The method of  claim 25  wherein a metered dose inhaler is used to administer the mometasone furoate in the dosage range of 50 to 1000 mcg/day. 
     
     
         27 . The method of  claim 25  wherein a dry powder inhaler is used to administer the mometasone furoate. 
     
     
         28 . The method of  claim 25  wherein the mometasone furoate is administered in a range of about 100 to 600 mcg/day. 
     
     
         29 . The method of  claim 25  wherein the mometasone furoate is administered in admixture with lactose.